IRWD240816C15000
- 0.05
- 0.000.00%
Ironwood Pharmaceuticals Newsroom
Ironwood Pharmaceuticals Analyst Ratings
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $14
Ironwood Pharmaceuticals: A Buy Rating Amidst Strong Product Positioning and Promising Clinical Data
Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge
Ironwood Pharmaceuticals Analyst Ratings
Ironwood Pharmaceuticals: Strong Buy Rating on LINZESS Performance and Apraglutide Market Potential
Ironwood Pharmaceuticals Analyst Ratings
Ironwood Pharmaceuticals Receives 'Buy' Rating From Analyst Amid Strong Performance and Promising Drug Pipeline
Ironwood Pharmaceuticals Analyst Ratings
Wells Fargo Initiates Coverage On Ironwood Pharmaceuticals With Overweight Rating, Announces Price Target of $20
Ironwood Pharmaceuticals Analyst Ratings
Ironwood Pharmaceuticals' Apraglutide Shows Promising Results in STARS Nutrition and VectivBio Trials: An Emphasis on Jason Butler's Buy Rating
JMP Securities Initiates Coverage On Ironwood Pharmaceuticals With Market Outperform Rating, Announces Price Target of $22
Ironwood Pharmaceuticals Analyst Ratings
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating
Capital One Securities Initiates IRWD at Overweight With $15 Price Target
Ironwood Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Ironwood Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by Wells Fargo
Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $13
Ironwood Pharmaceuticals Analyst Ratings